
Ask a doctor about a prescription for OLMESARTAN/AMLODIPINE VIATRIS 40 mg/10 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan/Amlodipine Viatris 40 mg/10 mg Film-Coated Tablets EFG
olmesartan medoxomil/amlodipine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Olmesartan/Amlodipine Viatris contains two active substances called olmesartan medoxomil and amlodipine (as amlodipine besylate). Both substances help to control high blood pressure.
The action of both substances contributes to preventing the narrowing of blood vessels, so they relax and blood pressure decreases.
Olmesartan/Amlodipine Viatris is used to treat high blood pressure in patients whose blood pressure is not adequately controlled with olmesartan or amlodipine alone.
Do not take Olmesartan/Amlodipine Viatris
If you think you may be allergic, inform your doctor before taking Olmesartan/Amlodipine Viatris.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Olmesartan/Amlodipine Viatris.
Tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking olmesartan/amlodipine. Your doctor will decide whether to continue treatment. Do not stop taking olmesartan/amlodipine on your own.
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartan/Amlodipine Viatris”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you experience severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
As with any other medicine that lowers blood pressure, an excessive drop in blood pressure in patients with altered blood flow in the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
You must inform your doctor if you are pregnant or think you might be. Olmesartan/Amlodipine Viatris is not recommended during the first trimester of pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period (see section “Pregnancy and breast-feeding”).
Children and adolescents (under 18 years)
Olmesartan/Amlodipine Viatris is not recommended for children and adolescents under 18 years.
Other medicines and Olmesartan/Amlodipine Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Olmesartan/Amlodipine Viatris” and “Warnings and precautions”).
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking Olmesartan/Amlodipine Viatris with food and drinks
Olmesartan/Amlodipine Viatris can be taken with or without food. Take the tablets with a little liquid (such as a glass of water). If possible, take your daily dose at the same time each day, for example, at breakfast time.
People taking Olmesartan/Amlodipine Viatris must not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can cause an unpredictable increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure-lowering effect of Olmesartan/Amlodipine Viatris.
Elderly patients
If you are over 65 years old, your doctor will regularly check your blood pressure each time your dose is increased, to ensure that it does not drop too much.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Olmesartan/Amlodipine Viatris is somewhat smaller in black patients.
Pregnancy and breast-feeding
Pregnancy
You must inform your doctor if you are pregnant or think you might be.
Your doctor will advise you to stop taking Olmesartan/Amlodipine Viatris before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Olmesartan/Amlodipine Viatris. Olmesartan/Amlodipine Viatris is not recommended during the first trimester of pregnancy, and it must not be taken when you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period.
If you become pregnant while taking Olmesartan/Amlodipine Viatris, inform your doctor immediately.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. It has been shown that amlodipine passes into breast milk in small amounts. Olmesartan/Amlodipine Viatris is not recommended for breast-feeding mothers, and your doctor may choose another treatment if you wish to breast-feed, especially if your baby is newborn or premature.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
During treatment for high blood pressure, you may feel drowsy, feel sick, or dizzy, or have a headache. If this happens, do not drive or use machines until the symptoms have gone away. Consult your doctor.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Follow exactly the instructions of administration of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
If you take more Olmesartan/Amlodipine Viatris than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and rapid or slow heartbeat.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that can develop up to 24-48 hours after ingestion.
If you take more tablets than you should, or a child accidentally ingests some tablets, contact your doctor immediately or go to the nearest emergency center and take the medicine pack or this leaflet with you.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Telephone 91 562 04 20.
If you forget to take Olmesartan/Amlodipine Viatris
If you forget to take a dose, take your usual dose the next day. Do nottake a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Amlodipine Viatris
It is important to continue taking Olmesartan/Amlodipine Viatris unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If they occur, they are often mild and do not require interruption of treatment.
The following adverse effects may be serious, although they affect only a small group of people:
During treatment with Olmesartan/Amlodipino Viatris, allergic reactions may occur, which can affect the whole body, with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash. If this happens to you, stop taking Olmesartan/Amlodipino Viatris and consult your doctor immediately.
Olmesartan/Amlodipino Viatris may cause a marked decrease in blood pressure, in susceptible patients, or as a result of an allergic reaction. This can cause fainting or severe dizziness. If this happens to you, stop taking Olmesartan/Amlodipino Viatris, consult your doctor immediately, and remain lying down in a horizontal position.
Unknown frequency: If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with Olmesartan/Amlodipino Viatris a long time ago, contact your doctor immediatelywho will evaluate your symptoms and decide how to continue with blood pressure treatment.
Other possible adverse effects with Olmesartan/Amlodipino Viatris:
Frequent (may affect up to 1 in 10 people):
Dizziness; headache; swelling of the ankles, feet, legs, hands, or arms; fatigue.
Uncommon (may affect up to 1 in 100 people):
Dizziness when standing up; lack of energy; tingling or numbness of the hands or feet; vertigo; noticing heartbeats; rapid heartbeat; low blood pressure with symptoms such as dizziness, dizziness; difficulty breathing; cough; nausea; vomiting; indigestion; diarrhea; constipation; dry mouth; pain in the upper abdomen; skin rash; cramps; pain in arms and legs; back pain; feeling of urgency to urinate; sexual inactivity; inability to have or maintain an erection; weakness.
Some changes in the results of certain blood tests have also been observed:
Increased, as well as decreased levels of potassium in the blood, increased levels of creatinine in the blood, increased levels of uric acid, increased values of liver function tests (gamma glutamyl transferase levels).
Rare (may affect up to 1 in 1,000 people):
Hypersensitivity to the medicine; fainting; flushing and feeling of heat in the face; red hives with itching (urticaria); facial inflammation.
Adverse effects reported with the use of olmesartan medoxomil or amlodipine alone, but not with Olmesartan/Amlodipino Viatris, or with a higher frequency:
Olmesartan medoxomil
Frequent (may affect up to 1 in 10 people):
Bronchitis; sore throat; nasal congestion and secretion; cough; abdominal pain; viral gastroenteritis; diarrhea; indigestion; nausea; joint and bone pain; back pain; blood in the urine; urinary tract infection; chest pain; flu-like symptoms; pain. Changes in the results of blood tests, such as increased levels of a type of fat (hypertriglyceridemia); increased uric acid and urea in the blood and increased values of liver and muscle function tests.
Uncommon (may affect up to 1 in 100 people):
Reduction in the number of a type of blood cells called platelets, which can easily cause bruising or prolong bleeding time; rapid allergic reactions, which can affect the whole body and cause respiratory problems, as well as a rapid drop in blood pressure, which can even cause fainting (anaphylactic reactions); angina (pain or discomfort in the chest, known as angina pectoris); itching; skin rash; allergic skin rash; urticaria; facial swelling; muscle pain; discomfort.
Rare (may affect up to 1 in 1,000 people):
Inflammation of the face, mouth, and/or larynx (vocal cords); acute kidney failure and kidney failure; lethargy, intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Amlodipine
Very frequent (may affect more than 1 in 10 people):
Edema (fluid retention).
Frequent (may affect up to 1 in 10 people):
Abdominal pain; nausea; swelling of the ankles; feeling of sleep; flushing and feeling of heat in the face, visual disturbances (including double vision and blurred vision), noticing heartbeats, diarrhea, constipation, indigestion, cramps, weakness, difficulty breathing.
Uncommon (may affect up to 1 in 100 people):
Difficulty sleeping; sleep disorders; mood changes including anxiety; depression; irritability; tremors; taste disturbances; fainting; ringing in the ears (tinnitus); worsening of angina pectoris (pain or discomfort in the chest); irregular heartbeat; nasal secretion or congestion; hair loss; purple or colored spots on the skin due to small hemorrhages (purpura); skin discoloration; excessive sweating; skin rash; itching; red hives with itching (urticaria); joint or muscle pain; urination problems; need to urinate at night; increased need to urinate, increased breast size in men, chest pain; pain; feeling of discomfort; weight gain or loss.
Rare (may affect up to 1 in 1,000 people):
Confusion.
Very rare (may affect up to 1 in 10,000 people):
Decreased number of white blood cells, which could increase the risk of infections; decreased number of a type of blood cells called platelets, which could lead to the appearance of bruises and prolonged bleeding time; increased blood glucose; increased muscle tension or greater resistance to passive movement (hypertonia); tingling or numbness of the hands or feet; heart attack; inflammation of blood vessels; inflammation of the liver or pancreas; inflammation of the stomach wall; gum thickening; elevated liver enzymes; yellowing of the skin and eyes; increased sensitivity of the skin to light; allergic reactions, itching, rash, inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and rash, severe skin reactions, including intense skin rash, urticaria, redness of the body skin, severe itching, blisters, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis), sometimes very severe.
Unknown frequency (cannot be estimated from the available data):
Tremors, rigid posture, mask-like face, slow movements, and unsteady gait.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD or EXP. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines that you no longer need in the SIGRE point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of Olmesartán/Amlodipino Viatris
The active ingredients are olmesartan and amlodipine (as amlodipine besylate).
Each film-coated tablet contains 40 mg of olmesartan medoxomil and 10 mg of amlodipine (as amlodipine besylate).
The other components are:
Core of the tablet:
microcrystalline cellulose (E-460i), sodium lauryl sulfate (E-487), citric acid monohydrate (E-330), hydroxypropylcellulose (E-463), sodium croscarmellose (E-466), maltose, mannitol (E-421), low-substituted hydroxypropylcellulose (E-463), magnesium stearate (E-572).
Tablet coating (Opadry II Brown 85F565125):
partially hydrolyzed polyvinyl alcohol (E-1203), titanium dioxide (E-171), macrogol/PEG (E-1521), talc (E-553b), yellow iron oxide (E-172), red iron oxide (E-172).
Appearance of the product and package contents
Olmesartán/Amlodipino Viatris are film-coated tablets of brown color, round, biconvex, marked with "M" on one face and "OA3" on the other.
PVC/Alu/OPA-Alu blister pack containing 28 film-coated tablets.
PVC/Alu/OPA-Alu calendar blister pack containing 28 film-coated tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
Manufacturer
Mylan Hungary Kft.
H-2900 Komárom
Mylan útca 1
Hungary
Date of the last revision of this prospectus:February 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/
The average price of OLMESARTAN/AMLODIPINE VIATRIS 40 mg/10 mg FILM-COATED TABLETS in October, 2025 is around 21.43 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/AMLODIPINE VIATRIS 40 mg/10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.